APOLLOHOSP Q4 FY26 Results Analysis: PAT Surges 33%, Digital Health Turns Profitable

CompoundingAI Research Updated May 21, 2026 2 min read

APOLLOHOSP reported Q4 FY26 numbers with revenue of Rs. 6,606.00 Cr (+18.12% YoY) and PAT growth of +33.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 20, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 6,606.00 Cr (+18.12% YoY)
PAT (Q4)Rs. 551.30 Cr (+33.00% YoY)
EBITDA margin15.31% (+155 bps YoY)
EPS (Q4)Rs. 36.82 (+35.87% YoY)
Market capRs. 119,230.79 Cr
CMPRs. 8,313.00

Quarter Snapshot

Apollo Hospitals delivered exceptional Q4 FY26 results with revenue growth of 18.12% YoY and PAT surge of 33% YoY, beating management's mid-teens guidance. EBITDA margin expanded 155 bps demonstrating strong operating leverage. The Digital Health segment achieved its first full-year profitability with 490% YoY growth in segment results, validating the path to 7% margin target by Q4 FY27. Free Cash Flow doubled to Rs.8,937 Crore with improved capital structure (Debt/Equity at 0.57x), positioning the company well for sustained growth.

Key Investment Insights

Key Positives

  • Revenue grew 18.12% YoY to Rs.6,606 Crore
  • PAT to owners surged 33% YoY to Rs.551 Crore
  • EBITDA margin expanded 155 bps to 15.31%
  • Digital Health segment achieved first full-year profitability
  • Retail Health margin surged 516 bps YoY to 8.15%
  • Digital Health margin expanded 380 bps to 4.77%
  • CFO/PAT ratio strong at 1.43x
  • Free Cash Flow doubled to Rs.8,937 Crore
  • Debt/Equity improved from 0.61x to 0.57x
  • Healthcare Services revenue growth of 17.26% exceeded mid-teens guidance

Risk Factors

  • Other expenses grew 21.48% YoY, exceeding revenue growth
  • New hospital start-up losses of ~Rs.150 Cr projected over next year
  • Healthcare Services margin slightly declined 7 bps YoY to 18.44%
  • Working capital impact of Rs.7,703 Million in FY26
Share on X · LinkedIn

Disclaimer: This is an AI-generated analysis based on public filings. It is not investment advice, not a recommendation to buy/sell/hold any security, and is not prepared by a SEBI-registered Research Analyst or Investment Adviser.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now